Sommarutide is a new generation of GLP-1 (glucagon-like peptide-1) analogues. Sommarlutide is a long-acting formulation based on the basic structure of Liraglutide and is more effective in the treatment of type 2 diabetes. Compared to Liraclutide, sommarlutide has a longer fat chain and an increased hydrophobicity, but sommarlutide is modified by short chain PEG and its hydrophilicity is greatly enhanced. PEG modification can not only bind to albumin closely, cover the hydrolysis site of DPP-4 enzymatic action, but also reduce renal excretion, prolong biological half-life, and achieve a long cycle effect.
Somarlutide (USAN; Ozempic is a drug being developed by Danish company Novo Nordisk to treat type 2 diabetes. It is sold under the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it reduces blood sugar levels by increasing production. A team of Novo Nordisk researchers discovered in 2012 that it is a long-acting alternative to liraglutide. Clinical trials began in 2015 and phase 3 was completed in 2016. It applied for FDA approval in December 2016 and was approved by the FDA Advisory Committee in a 16-0 vote in October 2017. It can be used as either an injectable or oral drug.
Researchers at the University of Leeds reported in 2017 that it could also be used to treat obesity. It can reduce hunger, food cravings, and body fat.